公告称，公司收购未来医药多种微量元素注射液资产组，有助于优化公司产品结构，进一步拓宽疾病治 疗领域，有助于公司在当前国家大健康发展战略的背景下充分关注妇女、儿童和老年人的疾病治疗和健 康管理，为构建贯穿"儿童-成人-老年"的"全龄覆盖"健康产品与健康服务链条打下基础，完善企业战略 布局。 佐力药业（300181）(300181.SZ)发布公告，公司("甲方")于2025年12月12日与西藏未来生物医药股份有 限公司(以下简称"西藏未来")及其两家全资子公司许昌未来制药有限责任公司(以下简称"许昌未来")和 合肥市未来药物开发有限公司(以下简称"合肥未来")(以上交易对方合称"未来医药")签署了《多种微量 元素注射液资产组收购协议书》，拟以总价(含税)人民币3.56亿元收购其多种微量元素注射液资产组(以 下简称"资产组")。资产组的内容包括已上市品种"多种微量元素注射液(Ⅰ)"、"多种微量元素注射液 (Ⅱ)"和在研品种"多种微量元素注射液(Ⅲ)"的研发/生产技术资料、上市许可、商标、专利、合同权利与 义务、员工劳动关系等。 本次收购的资产组中，其中多种微量元素注射液(Ⅰ)和多种微量元素注射液(Ⅱ)已有多年的推广 ...

Core Viewpoint - Zhaoli Pharmaceutical (300181.SZ) announced the acquisition of a multi-trace element injection asset group from Tibet Future Biopharmaceutical Co., Ltd. for a total price of RMB 356 million, which will enhance the company's product structure and expand its treatment areas, particularly focusing on women's, children's, and elderly health management [1][2]. Group 1 - The acquisition includes the research and production technical data, marketing licenses, trademarks, patents, and employee labor relations related to the already marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)" [1]. - The acquisition is aligned with the national health development strategy, aiming to establish a comprehensive health product and service chain covering all age groups from children to the elderly [1]. - The asset group has demonstrated strong profitability, with a net profit of RMB 45.79 million achieved from January to September 2025, indicating good earning potential [2].

格隆汇12月14日丨佐力药业(300181.SZ)发布公告，公司于2025年12月12日与西藏未来生物医药股份有 限公司(以下简称"西藏未来")及其两家全资子公司许昌未来制药有限责任公司(以下简称"许昌未来")和 合肥市未来药物开发有限公司(以下简称"合肥未来")(以上交易对方合称"未来医药")签署了《多种微量 元素注射液资产组收购协议书》，拟以总价(含税)人民币35,600万元收购其多种微量元素注射液资产组 (以下简称"资产组")。资产组的内容包括已上市品种"多种微量元素注射液(Ⅰ)"、"多种微量元素注射液 (Ⅱ)"和在研品种"多种微量元素注射液(Ⅲ)"的研发/生产技术资料、上市许可、商标、专利、合同权利与 义务、员工劳动关系等。 ...

Core Viewpoint - Zhaoli Pharmaceutical (300181) announced the acquisition of a multi-trace element injection asset group from Tibet Future Biopharmaceutical Co., Ltd. for a total price of 356 million yuan, which includes both marketed and research products [1] Group 1: Acquisition Details - The asset group includes the marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the research product "Multi-trace Element Injection (III)" [1] - The acquisition encompasses research and production technical data, marketing licenses, trademarks, patents, contractual rights and obligations, and employee labor relations [1] Group 2: Strategic Implications - The acquisition is expected to optimize the company's product structure and expand its treatment areas, particularly focusing on diseases affecting women, children, and the elderly [1] - This move aligns with the national health development strategy, aiming to establish a comprehensive health product and service chain that covers all age groups from children to the elderly [1]

Core Viewpoint - Zhaoli Pharmaceutical has signed an asset acquisition agreement to purchase a variety of trace element injection assets from Tibet Future Biopharmaceutical Co., Ltd. for a total price of 356 million yuan, including tax [1] Group 1: Acquisition Details - The acquisition includes the research and production technical data, marketing approvals, trademarks, patents, contractual rights and obligations, and employee labor relations related to the products [1] - The asset group consists of the already marketed products "Multiple Trace Element Injection (I)" and "Multiple Trace Element Injection (II)", as well as the in-development product "Multiple Trace Element Injection (III)" [1]

Group 1 - The company announced a cash acquisition of assets from Future Pharmaceuticals for no more than 480 million yuan, including three types of microelement injection solutions and related intellectual property [1] - This acquisition is expected to constitute a significant asset restructuring and will not involve share issuance or change in control [1] - The company plans to disclose a formal proposal related to the transaction within six months and will continue to fulfill information disclosure obligations as necessary [1] Group 2 - The acquisition will enrich the company's product pipeline and align with its "health management for all ages" strategy, optimizing its product layout in the "anti-infection - chronic disease - nutritional support" sectors [2] - The microelement injection solutions have already established market sales, which could provide immediate revenue and profit growth for the company, enhancing its operational sustainability and profitability [2] - The acquired assets include a mature national sales channel and academic promotion system, which will help the company expand sales channels for its products, particularly in the pediatric flu medication market [2] Group 3 - The company specializes in antiviral and infectious disease prevention drugs, as well as treatments for major diseases like cancer and cardiovascular diseases [3] - It has developed a combined R&D system for innovative and generic drugs, with a production chain covering over 30 provinces in China [3] - The company reported a revenue of 40.62 million yuan in Q1 2025, a year-on-year decline of 70.21%, with a net loss of 8.03 million yuan [3]

Core Viewpoint - Company intends to acquire a group of assets from Future Pharmaceuticals for a cash consideration of up to 480 million yuan, which includes both marketed and in-development products related to multi-trace element injection solutions, enhancing its product pipeline and aligning with its health management strategy [1][2] Group 1 - The acquisition includes marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)" [1] - The transaction is expected to constitute a significant asset restructuring as per the regulations, and it will not involve share issuance or result in a change of control [1] - The acquisition aligns with the company's strategy to enhance its product matrix for "all-age health management" and optimize its product layout in "anti-infection, chronic disease, and nutritional support" [1] Group 2 - The asset group includes a well-established national sales channel and academic promotion system, which will help the company expand new sales channels for its products [2] - The existing sales network and academic promotion system are expected to significantly facilitate market access and coverage for the company's pediatric anti-influenza drugs [2]

Core Viewpoint - The company, Nanxin Pharmaceutical (688189.SH), has signed a purchase intention agreement to acquire a group of assets from Future Medicine for a cash consideration of up to 480 million yuan, which includes both marketed and in-development products related to multi-trace element injection solutions [1][2] Group 1 - The acquisition will include the marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)", along with associated R&D and production technical materials, trademarks, patents, customer data, and regulatory approvals [1] - This transaction is expected to constitute a significant asset restructuring as defined by the regulations governing listed companies, and it will not involve the issuance of new shares or result in a change of control for the company [1] - The acquisition aligns with the company's strategy to enhance its product pipeline and optimize its product layout in the "anti-infection - chronic disease - nutritional support" categories, supporting its broader "healthcare" development strategy [1] Group 2 - The asset group includes a well-established national sales channel and academic promotion system, which will help the company expand new sales channels for its products and significantly enhance market access and coverage for its pediatric anti-influenza medications [2]